Biotech - Spark Newswire

7 minute read

Cellectis Highlights Innovation Days Event

Today, 9:53 PM

Cellectis S.A. (NASDAQ:CLLS) (the "Company"), a clinical-stage biotechnological company employing its core proprietary technologies to develop products based on gene-editing with a portfolio of allogeneic

CLLS

1 minute read

Pharmaceuticals Announces Preliminary Safety And Dosimetry Results From Single-Dose Portion Of Phase 1 Study Of FPI-1434 ; Says Candidate ‘demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity’

By Bill Haddad

Today, 9:53 PM

Product candidate FPI-1434, administered at three different dose levels, demonstrated a favorable safety profile with no drug-related serious adverse events or dose-limiting toxicity Imaging shows drug uptake across

FUSN

1 minute read

Biogen Announces Phase 3 STAR Study Of BIIB111/AAV2-REP1 In Choroideremia Did Not Meet Primary Or Key Secondary Endpoints

By Bill Haddad

Today, 9:53 PM

Biogen Inc. (NASDAQ:BIIB) today announced topline results from the Phase 3 STAR study of timrepigene emparvovec (BIIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia. The STAR

BIIB

4 minute read

Novavax Vs. Pfizer Vs. Moderna: How COVID-19 Vaccines Stack Up

By Shanthi Rexaline

Today, 9:53 PM

It was "better late than never" for Novavax, Inc. (NASDAQ: NVAX), as the biopharma finally got around to announcing interim results from the U.S. and Mexico leg of the Phase 3 study of NVX-CoV2371, its vaccine candidate against the novel coronavirus.

BNTX

1 minute read

FDA
News

Longeveron Shares Tick Higher; Co Publishes Study Titled ‘Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase IIb Clinical Trial. (ELPISII)’ To ClinicalTrials.Gov Site

By Benzinga Newsdesk

Today, 9:53 PM

https://clinicaltrials.gov/ct2/show/NCT04925024

LGVN

1 minute read

FDA
News

Karyopharm Therapeutics Posts Study Titled ‘Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma’ To ClinicalTrials.Gov Site

By Benzinga Newsdesk

Today, 9:53 PM

https://clinicaltrials.gov/ct2/show/NCT04925193

KPTI

1 minute read

FDA
News

UK Analysis Says Vaccines High Effective Against Hospitalization With Delta Variant; Says Pfizer Shot 96% Effective Against Hospitalization After 2 Doses; Says Astra Zeneca Shot 92% Effective After 2 Doses

By Benzinga Newsdesk

Today, 9:53 PM

-Dow Jones

AZN

1 minute read

Epizyme’s Multiple Myeloma Drug Candidate Inhibits Tumors In Animal Models

By Vandana Singh

Today, 9:53 PM

Epizyme Inc (NASDAQ:EPZM) has reported positive data from mouse studies for potential first-in-class therapy, EPZ-719, that targets the enzyme SETD2. The…

EPZM

1 minute read

Omeros’ Narsoplimab Associated With Improvement In Organ Function In Stem Cell Transplant Patients

By Vandana Singh

Today, 9:53 PM

Omeros Corporation (NASDAQ:OMER) has announced the presentation of data on organ function improvement from its pivotal trial of narsoplimab for the…

OMER

1 minute read

Terns Shares Drop After Mixed Results From Mid-Stage NASH Trial With FXR Agonist

By Vandana Singh

Today, 9:53 PM

Terns Pharmaceuticals Inc (NASDAQ:TERN) reported top-line results from the Phase 2a LIFT trial of TERN-101, a liver-distributed farnesoid X receptor (FXR)…

TERN